Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Pulmonary Arterial Hypertension (STELLAR)
NCT04576988Phase 3Completed
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sotatercept Arm with Placebo Arm (2 arms). Primary endpoints: Change From Baseline in 6-Minute Walk Distance at 24 weeks, Number of Participants Who Experienced an Adverse Event at 24 weeks and 1 more. Started Jan 2021; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04576988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576988.